Prolonged administration of bile salts for gallstone dissolution and its effect on rectal epithelial cell proliferation.
Bile acids and cholesterol metabolites may play a role in large bowel carcinogenesis. Currently, the bile acids chenodeoxycholic (CDCA) and ursodeoxycholic acid (UDCA) are being used for dissolution of cholesterol gallstones in surgical high-risk patients. The effect of prolonged exogenous bile acid intake on rectal epithelial cell proliferation, as a marker for preneoplasia, was evaluated in 19 patients selected for treatment. They were divided into two groups: nine patients received CDCA, 15 mg/kg/day for a mean duration of 11.0 months, while 11 patients received UDCA, 10 mg/kg/day for a mean duration of 9.2 months. Rectal biopsies taken before treatment and at one, three, six, and 12 months of treatment were analyzed and evaluated by three proliferative parameters including labeling index (LI), distribution of labeled cells, and total cells per crypt column. No significant alterations in epithelial cell proliferation were observed among patients treated with UDCA or CDCA with the exception of the number of cells per crypt column which, in the latter instance, deviated only slightly from the predicted values. The lack of major persistent alterations in the proliferative behavior of rectal epithelial cells does not justify any change in the selection of patients for gallstone therapy, but cannot exclude the potentially deleterious long-term effects of bile acid treatment.
D001345:Autoradiography; D001706:Biopsy; D002455:Cell Division / Q000187:drug effects; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D002769:Cholelithiasis / Q000628:therapy*; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D006801:Humans; D011230:Precancerous Conditions / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000139:chemically induced; D012007:Rectum / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage* / Q000009:adverse effects
D003840:Deoxycholic Acid; D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid